Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: Evidence for additional functions of EYS

Muscle and Nerve

Volumn 44, Issue 4, 2011, Pages 531-538

  Isackson, Paul J ^a   Ochs Balcom, Heather M ^b   Ma, Changxing ^b   Harley, John B ^c   Peltier, Wendy ^d   Tarnopolsky, Mark ^e   Sripathi, Naganand ^f   Wortmann, Robert L ^g   Simmons, Zachary ^h   Wilson, Jon D ⁱ   Smith, Stephen A ^j   Barboi, Alexandru ^d   Fine, Edward ^a   Baer, Alan ^k   Baker, Steven ^e   Kaufman, Kenneth ^c   Cobb, Beth ^l   Kilpatrick, Jeffrey R ^l   Vladutiu, Georgirene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f HENRY FORD HOSPITAL   (United States)

^g DARTMOUTH MEDICAL SCHOOL   (United States)

^h PENN STATE COLLEGE OF MEDICINE   (United States)

ⁱ LOUISIANA STATE UNIVERSITY   (United States)

^j HENNEPIN COUNTY MEDICAL CENTER   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

more..

Author keywords

Agrin; Genetic association; Muscle; Myopathy; Notch; Spinal cord; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPLEMENTARY DNA; EYES SHUT HOMOLOG PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; PROTEIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHROMOSOME 6; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PRIORITY JOURNAL; RETINA; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL CORD;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 6; COMPUTATIONAL BIOLOGY; EXONS; EYE PROTEINS; FEMALE; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 80052913078     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22115     Document Type: Article

References (45)

1. Clark LT. Treating dyslipidemia with statins: the risk benefit profile. Am Heart J 2003;145:387-396.
2. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997;278:313-321.
3. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-295.
4. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 2000;22:441-457.
5. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-1107.
6. Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheum 2008;20:648-655.
7. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210: 94-102.
8. Laaksonen R, Katajamaa M, Paiva H, Sysi-Aho M, Saarinen L, Junni P, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 2006;1:e97.
9. Nakahara K, Kuriyama M, Sonoda Y, Yoshidome H, Nakagawa H, Fujiyama J, et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 1998;152:99-106.
10. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-8934.
11. Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005;62:1709-1712.
12. Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005;31:572-580.
13. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-162.
14. Giordano N, Senesi M, Mattii G, Battisti E, Villanova M, Gennari C. Polymyositis associated with simvastatin. Lancet 1997;349:1600-1601.
15. Noel B, Cerottini J-P, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med 2001;110:570-571.
16. Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arth Rheum 2006;55:551-557.
17. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002;58:1333-1337.
18. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome. Drug Safety 2007;30:515-525.
19. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008;359:789-799.
20. Abd El-Aziz MM, Barragan I, O'Driscoll CA, Goodstadr L, Prigmore E, Borrego S, et al. EYS, encoding an ortholog of Drosophila spacemaker, is mutated in autosomal recessive retinitis pigmentosa. Nat Genet 2008;40:1285-1287.
21. Collin RWJ, Littink KW, Klevering BJ, Ingeborgh van den Born L, Koenekoop RK, Zonneveld MN, et al. Identification of a 2 Mb human ortholog of Drosophila eyes shut/spacemaker that is mutated in patients with retinitis pigmentosa. Am J Hum Genet 2008;83: 594-603.
22. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin associated myopathy with normal and abnormal creatine kinase: clinical, pathological and biochemical features. Ann Intern Med 2002;137:581-585.
23. Gu YY, Harley ITW, Henderson LB, Aronow BJ, Vietor I, Huber LA, et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 2009;458:1039-1042.
24. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
25. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005; 37:1341-1344.
26. Sham P, Bader JS, Craig I, O'Donovan M, Owen M. DNA pooling: a tool for large-scale association studies. Nat Rev Genet 2002;3:862-871.
27. Macgregor S, Visscher PM, Montgomery G. Analysis of pooled DNA samples on high density arrays without prior knowledge of differential hybridization rates. Nucleic Acids Res 2006;34:e55.
28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a toolset for whole-genome association and population- based linkage analysis. Am J Hum Genet 2007;81:559-575.
29. Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 2002;21:35-50.
30. Scotton P, Bleckmann D, Stebler M, Sciandra F, Brancaccio A, Meier T, et al. Activation of muscle-specific receptor tyrosine kinase and binding to dystroglycan are regulated by alternative mRNA splicing of agrin. J Biol Chem 2006;281:36835-36845.
31. Husain N, Pellikka M, Hong H, Klimentova T, Choe KM, Clandinin TR, et al. The agrin/perlecan-related protein eyes shut is essential for epithelial lumen formation in the Drosphila retina. Dev Cell 2006; 11:483-493.
32. Zelhof AC, Hardy RW, Becker A, Zuker CS. Transforming the architecture of compound eyes. Nature 2006;443:696-699.
33. Cook B, Hardy RW, McConnaughey WB, Zuker CS. Preserving cell shape under environmental stress. Nature 2008;452:361-365.
34. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284: 770-776.
35. Garg V, Muth AN, Ransom JF, Shluterman MK, Barnes R, King IN, et al. Mutations in Notch1 cause aortic valve disease. Nature 2005; 437:270-274.
36. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997;16:243-251.
37. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-710.
38. Conboy IM, Conboy MJ, Smythe GM, Rando TA. Notch-mediated restoration of regenerative potential to aged muscle. Science 2003; 302:1575-1577.
39. Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Raven R, Poser SW, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006;442:823-826.
40. Rudenko G, Nguyen T, Chelliah Y, Sudhof TC, Deisenhofer J. The structure of the ligand-binding domain of neurexin 1beta: regulation of LNS domain function by alternative splicing. Cell 1999;99:93-101.
41. Hohenester E, Engel J. Domain structure and organization in extracellular matrix proteins. Matrix Biol 2002;21:115-128.
42. Grishkovskaya I, Avvakumov GV, Sklenar G, Dales D, Hammond GL, Muller YA. Crystal structure of human sex hormone-binding globulin: steroid transport by a laminin G-like domain. EMBO J 2000;19: 504-512.
43. Stetefeld J, Alexandrescu AT, Maciejowski MW, Jenny M, Rathgeb-Szabo L, Schulthess T, et al. Modulation of agrin function by alternative splicing and Ca2{thorn} binding. Structure 2004;12:503-515.
44. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-1616.
45. Rossi JS, McLeod HL. The pharmacogenetics of statin therapy. J Am Coll Cardiol 2009;54:1617-1618.